Overview of the evolution of pulmonary hypertension in interstitial lung disease

Pulmonary hypertension associated to lung diseases (Group 3) has worse prognosis and overall survival as compared to other pulmonary hypertension groups. Pulmonary hypertension in interstitial lung diseases was associated with higher mortality, more pronounced dysnea, lower DLCO, lower PaO2, lower exercise capacity and increase risk of exacerbation of fibrosis, and impacts survival and quality of life. Currently no standard guidelines regarding screening or early detection for PH in patients with ILD, however, clinical features, physical examinations, and pulmonary function testing (DLCO, FVC/DLCO ratio, and exercise testing, including CPET), blood biomarkers such as NT-proBNP, ECG or echocardiography might help to determine further diagnosis approach. There are landscape trials for PH-ILD, include BPHIT study, ARTEMIS-PH, INCREASE-trial, INCREASE-OLD. In this presentation, epidemiology, pathogenesis, diagnosis, treatments approach will be discussed and presented.